About all

Skin yeast infection images. Comprehensive Guide to Skin Yeast Infection: Symptoms, Treatment, and Prevention

What are the common symptoms of skin yeast infections. How can skin yeast infections be effectively treated. What preventive measures can be taken against skin yeast infections. How do antifungal medications work in treating skin yeast infections. What are the differences between topical and oral antifungal treatments. How long does it typically take to treat a skin yeast infection. What are the potential complications of untreated skin yeast infections.

Understanding Skin Yeast Infections: Causes and Risk Factors

Skin yeast infections, also known as cutaneous candidiasis, are common fungal infections that affect various parts of the body. These infections are primarily caused by an overgrowth of Candida species, with Candida albicans being the most prevalent culprit. Understanding the causes and risk factors is crucial for effective prevention and treatment.

Common Causes of Skin Yeast Infections

  • Warm and moist environments
  • Poor hygiene
  • Weakened immune system
  • Tight-fitting clothing
  • Prolonged use of antibiotics
  • Hormonal imbalances
  • Diabetes

Why do some people seem more prone to skin yeast infections? Certain factors can increase susceptibility, including obesity, pregnancy, and conditions that cause excessive sweating. Additionally, individuals with compromised immune systems, such as those with HIV/AIDS or undergoing chemotherapy, are at higher risk.

Recognizing the Symptoms of Skin Yeast Infections

Identifying the symptoms of a skin yeast infection is crucial for prompt treatment. While symptoms can vary depending on the affected area, there are several common signs to watch for:

  • Redness and inflammation
  • Itching and burning sensation
  • Rash with small red bumps or pustules
  • Scaling or flaking of the skin
  • Cracking or fissuring in skin folds

Can skin yeast infections occur anywhere on the body? Indeed, these infections can develop in various locations, including the groin (jock itch), feet (athlete’s foot), under the breasts, and in skin folds. In infants, diaper rash is often caused by yeast overgrowth.

Effective Treatment Options for Skin Yeast Infections

Treating skin yeast infections typically involves a combination of topical and, in some cases, oral antifungal medications. The choice of treatment depends on the severity and location of the infection.

Topical Antifungal Treatments

Topical treatments are the first line of defense against skin yeast infections. These include:

  • Azole antifungals (e.g., clotrimazole, miconazole, ketoconazole)
  • Allylamine antifungals (e.g., terbinafine)
  • Polyene antifungals (e.g., nystatin)

How long should topical treatments be applied? Most topical antifungals are used for 1-2 weeks, but treatment duration can vary based on the specific medication and severity of the infection. It’s crucial to complete the full course of treatment, even if symptoms improve, to prevent recurrence.

Oral Antifungal Medications

For more severe or persistent infections, oral antifungal medications may be prescribed. These include:

  • Fluconazole
  • Itraconazole
  • Terbinafine

When are oral antifungals necessary? Oral medications are typically reserved for widespread infections, those that don’t respond to topical treatments, or in cases where the infection has spread to deeper layers of skin or nails.

Natural Remedies and Home Care for Skin Yeast Infections

While medical treatments are often necessary, some natural remedies and home care practices can complement conventional therapies:

  • Tea tree oil (diluted)
  • Coconut oil
  • Apple cider vinegar baths
  • Probiotic supplements
  • Garlic (both topical and dietary)

Are natural remedies as effective as antifungal medications? While some natural remedies show promise, they generally aren’t as potent or fast-acting as prescription antifungals. It’s important to consult with a healthcare provider before relying solely on natural treatments, especially for severe or recurring infections.

Preventing Skin Yeast Infections: Key Strategies

Prevention is always better than cure when it comes to skin yeast infections. Implementing these strategies can significantly reduce the risk of developing an infection:

  1. Keep skin clean and dry, especially in skin folds
  2. Wear loose-fitting, breathable clothing
  3. Change out of wet or sweaty clothes promptly
  4. Use antifungal powders in prone areas
  5. Maintain good overall hygiene
  6. Manage underlying conditions like diabetes
  7. Avoid prolonged use of antibiotics when possible

How effective is good hygiene in preventing yeast infections? Proper hygiene practices can dramatically reduce the risk of skin yeast infections by creating an environment unfavorable for fungal growth. However, it’s important to note that excessive washing or use of harsh soaps can disrupt the skin’s natural balance and potentially increase susceptibility to infections.

Complications and When to Seek Medical Attention

While many skin yeast infections can be managed with over-the-counter treatments, some situations warrant professional medical attention:

  • Infections that don’t improve with home treatment
  • Recurring infections
  • Infections in sensitive areas (e.g., face, genitals)
  • Signs of spreading or systemic infection
  • Fever or other systemic symptoms

What are the potential complications of untreated yeast infections? If left untreated, skin yeast infections can spread to deeper layers of skin or even enter the bloodstream, causing a condition called candidemia. This is particularly dangerous for individuals with weakened immune systems.

Special Considerations for Different Age Groups

Skin yeast infections can affect individuals of all ages, but certain age groups may require special considerations:

Infants and Children

Diaper rash is a common form of yeast infection in infants. Prevention involves:

  • Frequent diaper changes
  • Allowing the diaper area to air dry
  • Using barrier creams

Elderly Individuals

Older adults may be more susceptible to skin yeast infections due to:

  • Weakened immune systems
  • Decreased mobility leading to prolonged skin moisture
  • Multiple medications that can affect skin health

How should treatment approaches differ for these age groups? For infants and elderly individuals, gentler treatments and closer monitoring may be necessary. It’s crucial to consult with a healthcare provider to determine the most appropriate and safe treatment plan.

The Role of Diet in Managing Skin Yeast Infections

While the direct impact of diet on skin yeast infections is still a subject of research, some dietary modifications may support overall skin health and immune function:

  • Reducing sugar and refined carbohydrate intake
  • Incorporating probiotic-rich foods
  • Consuming foods with antifungal properties (e.g., garlic, coconut oil)
  • Staying hydrated
  • Ensuring adequate intake of vitamins and minerals

Can dietary changes alone cure a skin yeast infection? While a healthy diet can support the body’s natural defenses against fungal overgrowth, it’s unlikely to cure an active infection on its own. Dietary changes should be seen as a complementary approach to medical treatments rather than a replacement.

Understanding skin yeast infections, their causes, symptoms, and treatment options is crucial for effective management and prevention. By recognizing early signs, implementing proper hygiene practices, and seeking timely medical attention when necessary, individuals can minimize the impact of these common but troublesome infections. Remember, while over-the-counter treatments are often effective, persistent or severe infections should always be evaluated by a healthcare professional to ensure appropriate care and prevent potential complications.

Therapy of Skin, Hair and Nail Fungal Infections

1. Gupta A.K., Sauder D.N., Shear N.H. Antifungal agents: An overview. Part I. J. Am. Acad. Dermatol. 1994;30:677–698. doi: 10.1016/S0190-9622(08)81495-8. [PubMed] [CrossRef] [Google Scholar]

2. Gupta A.K., Sauder D.N., Shear N.H. Antifungal agents: An overview. Part II. J. Am. Acad. Dermatol. 1994;30:911–933. doi: 10.1016/S0190-9622(94)70112-1. [PubMed] [CrossRef] [Google Scholar]

3. Crawford F., Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst. Rev. 2007;3:CD001434. doi: 10.1002/14651858.CD001434.pub2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Rotta I., Ziegelmann P.K., Otuki M.F., Riveros B.S., Bernardo N.L., Correr C.J. Efficacy of topical antifungals in the treatment of dermatophytosis: A mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149:341–349. doi: 10.1001/jamadermatol.2013.1721. [PubMed] [CrossRef] [Google Scholar]

5. Gupta A.K., Einarson T.R., Summerbell R.C., Shear N.H. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs. 1998;55:645–674. doi: 10.2165/00003495-199855050-00004. [PubMed] [CrossRef] [Google Scholar]

6. Weinberg J.M. Increasing Patient Adherence in Antifungal Infection Treatment. J. Clin. Aesthet. Dermatol. 2009;2:38–42. [PMC free article] [PubMed] [Google Scholar]

7. Ramam M., Prasad H.R., Manchanda Y., Khaitan B.K., Banerjee U., Mukhopadhyaya A., Gogtay J.A. Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis Indian J. Dermatol. Venereol. Leprol. 2003;69:154–158. [PubMed] [Google Scholar]

8. Gupta A.K., Bluhm R. Ciclopirox (Loprox) gel for superficial fungal infections. Skin Ther. Lett. 2004;9:4–5. [PubMed] [Google Scholar]

9. Bakos L., Brito A.C., Castro L.C., Gontijo B., Lowy G., Reis C.M.S., Zaitz C. Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. Pediatr. Infect. Dis. J. 1997;16:545–548. doi: 10.1097/00006454-199706000-00002. [PubMed] [CrossRef] [Google Scholar]

10. Borelli C., Klövekorn G., Ernst T.M., ödeker R.H., Korting H.C., Neumeister C. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis. Am. J. Clin. Dermatol. 2007;8:371–378. doi: 10.2165/00128071-200708060-00007. [PubMed] [CrossRef] [Google Scholar]

11. Fredriksson T. Treatment of Dermatomycoses with Topical Tioconazole and Miconazole. Dermatology. 1983;166:14–19. doi: 10.1159/000249910. [PubMed] [CrossRef] [Google Scholar]

12. Benfield P., Clissold S.P. Sulconazole A Review of its Antimicrobial Activity and Therapeutic Use in Superficial Dermatomycoses. Drugs. 1988;35:143–153. doi: 10.2165/00003495-198835020-00004. [PubMed] [CrossRef] [Google Scholar]

13. Jerajani H., Janaki C., Kumar S., Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study. Indian J. Dermatol. 2013;58:34–38. doi: 10.4103/0019-5154.105284. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Veraldi S., Persico M.C., Schianchi R. Isoconazole nitrate vs isoconazole nitrate and diflucortolone valerate in the treatment of tinea inguinalis: Results of a multicenter retrospective study. J. Drugs Dermatol. 2012;11:E70–E73. [PubMed] [Google Scholar]

15. Rotta I., Sanchez A., Gonçalves P.R., Otuki M.F., Correr C.J. Efficacy and safety of topical antifungals in the treatment of dermatomycosis: A systematic review. Br. J. Dermatol. 2012;166:927–933. doi: 10.1111/j.1365-2133.2012.10815.x. [PubMed] [CrossRef] [Google Scholar]

16. El-Gohary M., van Zuuren E.J., Fedorowicz Z., Burgess H., Doney L., Stuart B., Little P. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst. Rev. 2014;8:CD009992. doi: 10.1002/14651858.CD009992.pub2. [PubMed] [CrossRef] [Google Scholar]

17. Evans E.G. Tinea pedis: Clinical experience and efficacy of short treatment. Dermatology. 1997;194:3–6. doi: 10.1159/000246173. [PubMed] [CrossRef] [Google Scholar]

18. Budimulja U., Bramono K., Urip K.S., Basuki S., Widodo G., Rapatz G., Paul C. Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study. Mycoses. 2001;44:300–306. doi: 10.1111/j.1439-0507.2001.00672.x. [PubMed] [CrossRef] [Google Scholar]

19. Ortonne J.P., Korting H.C., Viguié-Vallanet C., Larnier C., Savaluny E. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): A randomized, double-blind, placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 2006;20:1307–1313. doi: 10.1111/j.1468-3083.2006.01807.x. [PubMed] [CrossRef] [Google Scholar]

20. Plaum S., Verma A., Fleischer A.B., Jr., Hardas B. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2% J. Drugs Dermatol. 2013;12:1004–1008. [PubMed] [Google Scholar]

21. Tanuma H., Doi M., Ohta Y., Abe M., Kume H., Mukai H., Katsuoka K. Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin) Mycoses. 2001;44:287–299. doi: 10.1046/j.0933-7407.2001.00653.x. [PubMed] [CrossRef] [Google Scholar]

22. Keyser P.D., Backer M.D., Massart D.L., Westelinck K.J. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): A double-blind, multicentre study. Br. J. Dermatol. 1994;130:22–25. doi: 10.1111/j.1365-2133.1994.tb06089.x. [PubMed] [CrossRef] [Google Scholar]

23. Saul A., Bonifaz A. Itraconazole in common dermatophyte infections of the skin: Fixed treatment schedules. J. Am. Acad. Dermatol. 1990;23:554–558. doi: 10.1016/0190-9622(90)70253-E. [PubMed] [CrossRef] [Google Scholar]

24. Bell-Syer S.E., Khan S.M., Torgerson D.J. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst. Rev. 2012;10:CD003584. doi: 10.1002/14651858.CD003584.pub2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Degreef H.J., DeDoncker P.R. Current therapy of dermatophytosis. J. Am. Acad. Dermatol. 1994;31:S25–S30. doi: 10.1016/S0190-9622(08)81263-7. [PubMed] [CrossRef] [Google Scholar]

26. Clinicaltrials.gov Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis 2016. [(accessed on 1 June 2018)]; Available online: https://clinicaltrials.gov/ct2/show/{“type”:”clinical-trial”,”attrs”:{“text”:”NCT02755857″,”term_id”:”NCT02755857″}}NCT02755857

27. Nozickova M., Koudelkova V., Kulikova Z., Malina L., Urbanowski S., Silny W. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int. J. Dermatol. 1998;37:703–705. doi: 10.1046/j.1365-4362.1998.00541.x. [PubMed] [CrossRef] [Google Scholar]

28. Stary A., Sarnow E. Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatology. 1998;196:237–241. doi: 10.1159/000017881. [PubMed] [CrossRef] [Google Scholar]

29. Montero-Gei F., Perera A. Therapy with Fluconazole for Tinea Corporis, Tinea Cruris, and Tinea Pedis. Clin. Infect. Dis. 1992;14:S77–S80. doi: 10.1093/clinids/14.Supplement_1.S77. [PubMed] [CrossRef] [Google Scholar]

30. Re V.L., Carbonari D.M., Lewis J.D., Forde K.A., Goldberg D.S., Reddy K.R., Schneider J.L. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. Am. J. Med. 2016;129:283–291. [PMC free article] [PubMed] [Google Scholar]

31. Jachiet M., Lanternier F., Rybojad M., Bagot M., Ibrahim L., Casanova J.L., Bouaziz J.D. Posaconazole Treatment of Extensive Skin and Nail Dermatophytosis Due to Autosomal Recessive Deficiency of CARD9. JAMA Dermatol. 2015;151:192–194. doi: 10.1001/jamadermatol.2014.2154. [PubMed] [CrossRef] [Google Scholar]

32. Cheng C.Y., Hsiao Y.H., Ko J.H. Disseminated deep dermatophytosis caused by Trichophyton rubrum in deep dermatophytosis affecting the skin. Dermatol. Sin. 2014;32:191–192. doi: 10.1016/j.dsi.2013.11.002. [CrossRef] [Google Scholar]

33. Decroix J., Ausma J., Cauwenbergh G., Borgers M., Wouters L. The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: Two exploratory phase IIa trials. Br. J. Dermatol. 2008;158:854–856. doi: 10.1111/j.1365-2133.2007.08420.x. [PubMed] [CrossRef] [Google Scholar]

34. Gupta A.K., Leonardi C., Stoltz R.R., Pierce P.F., Conetta B. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol. Venereol. 2005;19:437–443. doi: 10.1111/j.1468-3083.2005.01212.x. [PubMed] [CrossRef] [Google Scholar]

35. Welshenbaugh A.R., Angulo D., Ghannoum M. Time kill activity of albaconazole against agents of onychomycosis and tinea capitis; Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA. 17–20 September 2007; [Google Scholar]

36. Moriarty B., Hay R., Morris-Jones R. The diagnosis and management of tinea. BMJ. 2012;345:E4380. doi: 10.1136/bmj.e4380. [PubMed] [CrossRef] [Google Scholar]

37. Sahoo A.K., Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol. Online J. 2016;7:77–86. [PMC free article] [PubMed] [Google Scholar]

38. WHO Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults World Health Organization. [(accessed on 1 June 2018)];2014 Available online: http://www.who.int/maternal_child_adolescent/documents/skin-mucosal-and-hiv/en/

39. Edwards J.E. Candida species. In: Mandell G.L., Bennett J.E., Dolin R., editors. Principles and Practice of Infectious Diseases. 8th ed. Churchill Livingstone; Philadelphia, PA, USA: 2015. pp. 2879–2894. [Google Scholar]

40. Subissi A., Monti D., Togni G., Mailland F. Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs. 2010;70:2133–2135. doi: 10.2165/11538110-000000000-00000. [PubMed] [CrossRef] [Google Scholar]

41. Ellepola A.N., Samaranayake L.P. Oral candidal infections and antimycotics. Crit. Rev. Oral Biol. Med. 2000;11:172–198. doi: 10.1177/10454411000110020301. [PubMed] [CrossRef] [Google Scholar]

42. Grant S.M., Clissold S.P. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990;39:877–916. doi: 10.2165/00003495-199039060-00006. [PubMed] [CrossRef] [Google Scholar]

43. Grant S.M., Clissold S.P. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37:310–344. doi: 10.2165/00003495-198937030-00003. [PubMed] [CrossRef] [Google Scholar]

44. Sun J., Qi C., Lafleur M.D., Qi Q.G. Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China. Int. J. Oral Sci. 2009;1:156–161. doi: 10.4248/IJOS.09020. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

45. Ianas V., Matthias K.R., Klotz S.A. Role of posaconazole in the treatment of oropharyngeal candidiasis. Infect. Drug Resist. 2010;3:45–51. [PMC free article] [PubMed] [Google Scholar]

46. Gligorov J., Bastit L., Gervais H., Henni M., Kahila W., Lepille D. Candidoscope Study Group. Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: Results of the French CANDIDOSCOPE study. Int. J. Radiat. Oncol. Biol. Phys. 2011;80:532–539. doi: 10.1016/j.ijrobp.2010.02.006. [PubMed] [CrossRef] [Google Scholar]

47. Hu S.W., Bigby M. Pityriasis versicolor: A systematic review of interventions. Arch Dermatol. 2010;146:1132–1140. doi: 10.1001/archdermatol.2010.259. [PubMed] [CrossRef] [Google Scholar]

48. Gupta A.K., Foley K.A. Antifungal Treatment for Pityriasis Versicolor. J. Fungi. 2015;1:13–29. doi: 10.3390/jof1010013. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Gold M.H., Bridges T., Avakian E., Plaum S., Pappert E.J., Fleischer J.A., Hardas B. An open-label study of naftifine hydrochloride 1% gel in the treatment of tinea versicolor. Skinmed. 2011;9:283–286. [PubMed] [Google Scholar]

50. Di Fonzo E.M., Martini P., Mazzatenta C., Lotti L., Alvino S. Comparative efficacy and tolerability of Ketomousse (ketoconazole foam 1%) and ketoconazole cream 2% in the treatment of pityriasis versicolor: Results of a prospective, multicentre, randomised study. Mycoses. 2008;51:532–535. doi: 10.1111/j.1439-0507.2008.01508.x. [PubMed] [CrossRef] [Google Scholar]

51. Hull C.A., Johnson S.M. A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2. 5% in the treatment of pityriasis (tinea) versicolor. Cutis. 2004;73:425–429. [PubMed] [Google Scholar]

52. Crespo Erchiga V., Delgado Florencio V. Malassezia species in skin diseases. Curr. Opin. Infect. Dis. 2002;15:133–142. doi: 10.1097/00001432-200204000-00006. [PubMed] [CrossRef] [Google Scholar]

53. Farschian M., Yaghoobi R., Samadi K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J. Dermatol. Treat. 2002;13:73–76. doi: 10.1080/095466302317584421. [PubMed] [CrossRef] [Google Scholar]

54. Parsad D., Saini R., Negi K.S. Short-term treatment of Pityrosporum folliculitis: A double-blind placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 1998;11:188–190. doi: 10.1111/j.1468-3083.1998.tb00781.x. [PubMed] [CrossRef] [Google Scholar]

55. Naldi L. Seborrhoeic dermatitis. Clin. Evid. 2010;2010:1713. [PMC free article] [PubMed] [Google Scholar]

56. Elewski B.E. Tinea capitis: A current perspective. J. Am. Acad. Dermatol. 2000;42:1–20. doi: 10.1016/S0190-9622(00)90001-X. [PubMed] [CrossRef] [Google Scholar]

57. Fuller C.F., Barton R.C., Mohd Mustapa M.F. British Association of Dermatologists’ Guidelines for the Management of Tinea Capitis. [(accessed on 1 June 2018)];2014 Available online: http://www.bad.org.uk/shared/get-file.ashx?id=2022&itemtype=document

58. González U., Seaton T., Bergus G., Jacobson J., Martínez-Monzón C. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst. Rev. 2007;4:CD004685. [PubMed] [Google Scholar]

59. Tey H.L., Tan A.S., Chan Y.C. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J. Am. Acad. Dermatol. 2011;64:663–670. doi: 10.1016/j.jaad.2010.02.048. [PubMed] [CrossRef] [Google Scholar]

60. Babel D., Baughman S.A. Evaluation of the carrier state in juvenile tinea capitis caused by Trichophyton tonsurans. J. Am. Acad. Dermatol. 1989;21:1209–1212. doi: 10.1016/S0190-9622(89)70331-5. [PubMed] [CrossRef] [Google Scholar]

61. Alvarez M.S., Silverberg N.B. Tinea capitis. Cutis. 2006;78:189–196. [PubMed] [Google Scholar]

62. Hay R.J., Mackie R.M., Clayton Y.M. Tioconazole nail solution—An open study of its efficacy in onychomycosis. Clin. Exp. Dermatol. 1985;10:111–115. doi: 10.1111/j.1365-2230.1985.tb00537.x. [PubMed] [CrossRef] [Google Scholar]

63. Friedman-Birnbaum R., Cohen A., Shemer A., Bitterman O., Bergman R., Stettendorf S. Treatment of onychomycosis: A randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int. J. Dermatol. 1997;36:67–69. doi: 10.1046/j.1365-4362.1997.00024.x. [PubMed] [CrossRef] [Google Scholar]

64. Elewski B., Rich P., Pollak R., Pariser D.M., Watanabe S., Senda H., Olin J.T. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J. Am. Acad. Dermatol. 2013;68:600–608. doi: 10.1016/j.jaad.2012.10.013. [PubMed] [CrossRef] [Google Scholar]

65. Vlahovic T.C., Joseph W.S. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes. J. Drugs Dermatol. 2014;13:1186–1190. [PubMed] [Google Scholar]

66. Jones T., Tavakkol A. Safety and Tolerability of Luliconazole Solution 10-Percent in Patients with Moderate to Severe Distal Subungual Onychomycosis. Antimicrob. Agents Chemother. 2013;57:2684–2689. doi: 10.1128/AAC.02370-12. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

67. Zaug M., Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview) Clin. Exp. Dermatol. 1992;17:61–70. doi: 10.1111/j.1365-2230.1992.tb00281.x. [PubMed] [CrossRef] [Google Scholar]

68. Gupta A.K., Fleckman P., Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 2000;43:S70–S80. doi: 10.1067/mjd.2000.109071. [PubMed] [CrossRef] [Google Scholar]

69. Gupta A.K., Joseph W.S. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J. Am. Podiatr. Med. Assoc. 2000;90:495–501. doi: 10.7547/87507315-90-10-495. [PubMed] [CrossRef] [Google Scholar]

70. Elewski B.E., Aly R., Baldwin S.L., Soto R.F.G., Rich P., Weisfeld M., Pollak R. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. J. Am. Acad. Dermatol. 2015;73:62–69. doi: 10.1016/j.jaad.2015.04.010. [PubMed] [CrossRef] [Google Scholar]

71. Darkes M.J.M., Scott L.J., Goa K.L. Terbinafine: A review of its use in onychomycosis in adults. Am. J. Clin. Dermatol. 2003;4:39–65. doi: 10.2165/00128071-200304010-00005. [PubMed] [CrossRef] [Google Scholar]

72. Sigurgeirsson B., Billstein S., Rantanen T. LION. Study: Efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. Br. J. Dermatol. 1999;141:5–14. doi: 10.1046/j.1365-2133.1999.00008.x. [PubMed] [CrossRef] [Google Scholar]

73. De Sá D.C., Lamas A.P.B., Tosti A. Oral therapy for onychomycosis: An evidence-based review. Am. J. Clin. Dermatol. 2014;15:17–36. doi: 10.1007/s40257-013-0056-2. [PubMed] [CrossRef] [Google Scholar]

74. Tosti A., Piraccini B.M., Stinchi C., Venturo N., Bardazzi F., Colombo M.D. Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J. Am. Acad. Dermatol. 1996;34:595–600. doi: 10.1016/S0190-9622(96)80057-0. [PubMed] [CrossRef] [Google Scholar]

75. Maddin S., Quiring J., Bulger L. Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis. J. Drugs Dermatol. 2013;12:758–763. [PubMed] [Google Scholar]

76. Gupta A.K., Ryder J.E., Johnson A.M. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br. J. Dermatol. 2004;150:537–544. doi: 10.1046/j.1365-2133.2003.05728.x. [PubMed] [CrossRef] [Google Scholar]

77. Gupta A.K., De Doncker P., Scher R.K., Haneke M.D.E., Daniel R.C., André J., Baran R. Itraconazole for the treatment of onychomycosis. Int. J. Dermatol. 1998;37:303–308. doi: 10.1046/j.1365-4362.1998.00360.x. [PubMed] [CrossRef] [Google Scholar]

78. Elewski B.E. Onychomycosis: Pathogenesis, diagnosis and management. Clin. Microbiol. Rev. 1998;11:415–429. doi: 10.2165/00128071-200001010-00002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

79. Scher R.K., Breneman D., Rich P., Savin R.C., Feingold D.S., Konnikov N., Aly R. Once-weekly fluconazole (150, 300, 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J. Am. Acad. Dermatol. 1998;38:S77–S86. doi: 10.1016/S0190-9622(98)70490-6. [PubMed] [CrossRef] [Google Scholar]

80. Elewski B., Pollak R., Ashton S., Rich P., Schlessinger J., Tavakkol A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br. J. Dermatol. 2012;166:389–398. doi: 10.1111/j.1365-2133.2011.10660.x. [PubMed] [CrossRef] [Google Scholar]

81. Nematollahi A.R., Badiee P., Nournia E. The Efficacy of Ultraviolet Irradiation on Trichophyton Species Isolated From Nails. Jundishapur J. Microbiol. 2015;8:E18158. doi: 10.5812/jjm.18158v2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

82. Nair A.B., Vaka S.R.K., Murthy S.N. Transungual delivery of terbinafine by iontophoresis in onychomycotic nails. Drug Dev. Ind. Pharm. 2011;37:1253–1258. doi: 10.3109/03639045.2011.568946. [PubMed] [CrossRef] [Google Scholar]

83. Abadi D., Zderic V. Ultrasound-mediated nail drug delivery system. J. Ultrasound Med. 2011;30:1723–1730. doi: 10.7863/jum.2011.30.12.1723. [PubMed] [CrossRef] [Google Scholar]

84. Nenoff P., Grunewald S., Paasch U. Laser therapy of onychomycosis. J. Dtsch Dermatol. Ges. 2014;12:33–38. doi: 10.1111/ddg.12251. [PubMed] [CrossRef] [Google Scholar]

85. Bhatta A.K., Huang X., Keyal U. , Zhao J.J. Laser treatment for onychomycosis: A review. Mycoses. 2014;57:734–740. doi: 10.1111/myc.12225. [PubMed] [CrossRef] [Google Scholar]

86. Karsai S., Jager M., Oesterhelt A., Weiss C., Schneider S.W., Jünger M., Raulin C. Treating onychomycosis with the short-pulsed 1064-nm-Nd YAG laser: Results of a prospective randomized controlled trial. J. Eur. Acad. Dermatol. Venereol. 2017;31:175–180. doi: 10.1111/jdv.13798. [PubMed] [CrossRef] [Google Scholar]

87. De Morais O.O., Costa I.M.C., Gomes C.M., Shinzato D.H., Ayres G.M.C., Cardoso R.M. The use of the ER YAG 2940 nm laser associated with amorolfine lacquer in the treatment of onychomycosis. An. Bras. Dermatol. 2013;88:847–849. [PMC free article] [PubMed] [Google Scholar]

88. Zhang J., Lu S., Huang H., Li X., Cai W., Ma J., Xi L. Combination therapy for onychomycosis using a fractional 2940-nm Er:YAG laser and 5% amorolfine lacquer. Lasers Med Sci. 2016;31:1391–1396. doi: 10.1007/s10103-016-1990-z. [PubMed] [CrossRef] [Google Scholar]

89. Gilaberte Y., Robres M.P., Frias M.P., García-Doval I., Rezusta A., Aspiroz C. Methyl aminolevulinate photodynamic therapy for onychomycosis: A multicenter, randomized, controlled clinical trial. J. Eur. Acad. Dermatol. Venereol. 2017;31:347–354. doi: 10.1111/jdv.13842. [PubMed] [CrossRef] [Google Scholar]

90. Souza L.W.F., Souza S.V.T., Botelho A.C.C. Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: Treatment with photodynamic therapy based on methylene blue dye. An. Bras Dermatol. 2014;89:184–186. doi: 10.1590/abd1806-4841.20142197. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

91. Cohen P.R., Scher R.K. Topical and surgical treatment of onychomycosis. J. Am. Acad. Dermatol. 1994;31:S74–S77. doi: 10.1016/S0190-9622(08)81273-X. [PubMed] [CrossRef] [Google Scholar]

92. Di Chiacchio N., Kadunc B.V., de Almeida A.R.T., Madeira C.L. Nail abrasion. J. Cosmet. Dermatol. 2003;2:150–152. doi: 10.1111/j.1473-2130.2004.00095.x. [PubMed] [CrossRef] [Google Scholar]

93. Malay D.S., Yi S., Borowsky P., Downey M.S., Mlodzienski A.J. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: A randomized, controlled trial. J. Foot Ankle Surg. 2009;48:294–308. doi: 10.1053/j.jfas.2008.12.012. [PubMed] [CrossRef] [Google Scholar]

94. Jennings M.B., Pollak R., Harkless L.B., Kianifard F., Tavakkol A. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. J. Am. Podiatr. Med. Assoc. 2006;96:465–473. doi: 10.7547/0960465. [PubMed] [CrossRef] [Google Scholar]

95. Shemer A., Gupta A.K., Amichai B., Farhi R., Baran R., Daniel C.R., Foley K.A. An open comparative study of nail drilling as adjunctive treatment for toenail onychomycosis. J. Dermatol. Treat. 2016;27:480–483. doi: 10.3109/09546634.2016.1151856. [PubMed] [CrossRef] [Google Scholar]

96. Baran R., Hay R.J., Garduno J. I. Review of antifungal therapy, part II: Treatment rationale, including specific patient populations. J. Dermatol. Treat. 2008;19:168–175. doi: 10.1080/09546630701657187. [PubMed] [CrossRef] [Google Scholar]

97. D’almeida L.F.V., Papaiordanou F., Machado E.A., Loda G., Baran R., Nakamura R. Chronic paronychia treatment: Square flap technique. J. Am. Acad. Dermatol. 2016;75:398–403. [PubMed] [Google Scholar]

Candidiasis of the Skin: Symptoms, causes, and treatment

A certain amount of yeast lives on the skin normally, but too much yeast can cause an infection. Learn about the diagnosis and treatment for a skin yeast infection.

What is a skin yeast infection? | Symptoms | Causes | Diagnosis | Treatment

A skin yeast infection, also referred to as cutaneous candidiasis, is a common fungal infection that can occur in parts of the body where skin surfaces come together and create moist areas, such as the armpits, between the fingers or toes, the nails, under the breasts, skinfolds of the stomach, and in the genital area. Common yeast skin infections (or fungal skin infections) are caused by yeasts such as Candida or dermatophytes. Symptoms of a yeast infection vary depending on where the yeast is located. Symptoms of candidiasis may include an itchy rash or discharge. While yeast infections may feel uncomfortable, fortunately, they can be treated with various antifungal medicines. 

What is a yeast infection on the skin?

Candida is a yeast, or type of fungus, that normally lives on the skin and inside the body. A normal amount of Candida does not cause problems. However, a Candida infection may occur if there is an overgrowth of Candida (too much yeast) or if it enters deep into the body. The most common species of Candida is called Candida albicans (also known as C. albicans)

Skin yeast infection symptoms

The symptoms of a skin yeast infection can vary based on the location of the infection. General symptoms may include: 

  • Skin folds or navel: Rash, redness, oozing, pimples, itching, burning
  • Vagina in a female: Itching, burning, external redness, cottage cheese-like discharge
  • Penis in a male: Redness, scaling, and painful rash on the underside of the penis
  • Mouth (thrush): Redness, soreness, white patches on the tongue and inside of cheeks (difficulty swallowing may indicate that the esophagus is involved)
  • Corners of the mouth: Cracks or tiny cuts in the corners of the mouth
  • Nail beds: Swelling, pain, pus, discolored nails, nail separates from the nail bed 

What causes a yeast infection on the skin?

Certain risk factors or other health conditions make it easier for Candida to infect the skin, such as: 

  • Heat and humid weather.
  • Tight underclothing made of synthetic fibers.
  • Poor hygiene.
  • Not changing diapers frequently enough in babies or young children.
  • Not changing underwear enough in older adults.
  • A weak immune system due to diabetes, HIV/AIDS, or certain drugs that suppress the immune system, such as steroids (including inhaled steroids), chemotherapy, or immunosuppressant drugs taken after an organ transplant.
  • Pregnant women. 
  • Obesity. 
  • Denture use.
  • Antibiotic use (this is because the use of antibiotics kills the “good” bacteria, which may allow an overgrowth of Candida).
  • Other skin disorders, such as intertrigo (a rash that occurs between skin folds) or psoriasis (a skin condition that causes patches of thick, red skin and silvery scales)
  • People with diabetes mellitus, or high blood sugar, are at higher risk for developing yeast infections. It may be beneficial for anyone trying to avoid yeast infections to avoid foods that can spike blood sugar, such as white bread, pizza, pasta, white flour, white rice, sweets, and sweetened breakfast cereals, opting instead for healthier versions that contain whole grains and fiber, which can help slow or reduce blood sugar spikes.

In some severe cases, usually in individuals who have a weakened immune system, Candida may go beyond the surface and invade deeper tissues and the blood, causing a life-threatening condition called systemic candidiasis or invasive candidiasis. 

Candida yeast may spread from person to person, but that does not mean the infection is contagious. If you come in contact with someone who has a skin yeast infection, this does not mean you will get an infection. However, in some cases, the infection may transfer to another person. For example, a person with a weakened immune system may be more likely to catch the infection. Also, if a breastfeeding baby has oral candidiasis (thrush), the infection can transfer to the nursing mother from the baby’s saliva. Vaginal yeast infections (also known as candidal vulvovaginitis or vulvovaginal candidiasis) are not considered sexually transmitted infections because you can get a yeast infection without having sex. However, you can get a yeast infection from your partner. Latex condoms or dental dams can help prevent getting yeast infections—or passing them—through oral, vaginal, or anal sex.  

Yeast infection on skin diagnosis

If you think you have a skin yeast infection, visit your healthcare provider (or your child’s healthcare provider if your child is the patient). In many cases, your healthcare provider can identify a skin yeast infection by the type of rash. Your healthcare provider may want to take a skin sample by scraping off a tiny bit of skin (or residue from the rash) and testing it to ensure a proper diagnosis. Your healthcare provider will tell you what treatment will be most effective based on your symptoms, age, other medical conditions, and other individual factors.  

Skin yeast infection treatment

Your healthcare professional will determine the best treatment for you. Depending on symptoms, severity, and other factors, a skin yeast infection may require a topical antifungal OTC treatment, such as clotrimazole, or topical prescription medications, such as Nizoral (ketoconazole), to be applied to the affected area. In the case of a severe or recurring infection, the patient may require oral treatment, such as Diflucan (fluconazole), a prescription drug. 

A vagina infection caused by yeast may require an antifungal cream to be used inside the vagina. Sometimes, an external cream is used as well. Some patients will require oral medication for a vaginal yeast infection instead of—or in addition to—a vaginal cream.   

Adults with oral thrush may need antifungal medication such as an oral tablet or lozenge, or they may need to gargle with the liquid antifungal medication nystatin. Babies with thrush will require small amounts of liquid nystatin applied to the inside of the mouth up to four times daily and used for two days after symptoms resolve.  

Patients with recurring yeast infections will be tested for diabetes and evaluated for other medical conditions. This will tell the doctor if high blood sugar (or another medical condition) is contributing to yeast infections. Patients diagnosed with diabetes will require treatment by an endocrinologist. Individuals with recurring yeast infections may need preventive treatment and medication to treat infections when they occur. 

Insurance companies cover most prescription antifungal medications, especially if you use the generic version. You can always ask your pharmacist to check the price of your prescription with a free SingleCare card.

While being treated for a skin yeast infection, be alert to worsening symptoms and any redness, swelling, or pain, which could indicate a secondary bacterial infection. 

In addition to treating a skin yeast infection when it occurs, it is also important to take action to prevent future infections. Some tips include:

  • Keep the skin dry. After exercising or swimming, immediately remove wet or sweaty clothes. Shower, dry your skin, and change into clean clothes. Wash wet or sweaty clothing after each use. It is also a good idea to wear flip-flops or shower slides in the locker room.
  • Wear cotton, breathable underwear to help prevent a vaginal or genital yeast infection. Avoid tight-fitting, synthetic garments, opting for breathable cotton fabrics.
  • Women with frequent vaginal yeast infections should ask their healthcare professional if a daily probiotic may help.
  • Use drying powders to prevent yeast infections. 
  • Brush and floss your teeth every day. 
  • Maintain a healthy weight. Regardless of your weight, minimize refined carbohydrates and sugar. 
  • People with diabetes can help prevent yeast infections by controlling blood sugar. (Maintaining adequate blood sugar control also prevents many other complications of diabetes. )
  • Change diapers frequently in babies or infants who wear diapers and keep the area as dry as possible.
  • Ask your healthcare provider to review your medication list to see if any of your medications could be contributing to yeast infections. 

Although a yeast infection can be uncomfortable (or downright miserable), it is best to consult your healthcare provider for a diagnosis. Then, you can receive the correct treatment, institute any lifestyle changes necessary to help prevent future yeast infections, ask any questions you may have, and be on your way to feeling better in no time. 

Malassezia Fungus Possible Cause of Skin Disease| iHerb Blog

The information in this blog has not been verified by your local public health authority and is not intended as a diagnosis, treatment, or medical advice.
Read more

Mala… what?

What is Malassezia?

Malassesia is a type of yeast that lives on everyone’s skin. The yeast fungus Malassezia loves to live in hair follicles that are saturated with sebum. This fungus is a natural inhabitant of human skin, so there is nothing shameful or unpleasant about it. However, with overgrowth or a reaction to Malassezia, a range of skin problems can occur.

I estimate that a large number of the skin conditions that I see and treat in my practice can be attributed to some degree to fungal overgrowth. Diseases of this kind are very common!

Yeast thrives particularly well in warm, humid environments, so skin problems caused by yeast overgrowth are more common during the summer months, in hot, humid climates, and in people who sweat excessively or produce more sebum. Taking antibiotics, immunosuppressive drugs, and clothing and skin care products that are occlusive, meaning they don’t breathe, can also contribute to yeast overgrowth.

The most common skin conditions that can be caused by the yeast Malassezia are seborrheic dermatitis, versicolor and acne fungus. Below I will tell you what you need to know about each of these diseases, and then I will tell you about my favorite remedies for treating fungal skin diseases.

Seborrheic dermatitis

Seborrheic dermatitis is, in fact, the same dandruff. These are yellow, oily, scaly deposits and sometimes redness that can appear on the scalp, in the ears, between the eyebrows, around the nose and on the chest. This is a very common disease. It most often occurs in men, patients with neurological diseases (dementia, Parkinson’s disease), and also in people who cannot or do not wash their hair often enough. The exact cause of the disease is unknown, but one of the main causative factors is thought to be an overgrowth of the yeast Malassezia or an abnormal overreaction of the body to it. If left untreated, seborrheic dermatitis can sometimes cause itching, burning, or simply discomfort due to flaky scales that show up on skin and clothing.

One of the key components of the treatment for seborrheic dermatitis is the application of shampoo directly to the scalp to manually help remove dead skin cells and sebum. For people who don’t wash their hair very often, I also generally recommend washing their hair more often.

versicolor

versicolor is another common skin disease. It appears as slightly scaly patches of skin of an unusual color, predominantly on the chest, abdomen, and back. The word “multi-colored” means that in different people it can look like spots of different colors. Skin patches may be hypopigmented (lighter whitish), pink or hyperpigmented (darker tan/brown). Pityriasis versicolor is more common during the summer months when the weather is warm and people sweat more. Also, because the sun stimulates the skin to produce more pigment, the rash is often more noticeable in the summer. Therefore, sun protection can help reduce the visibility of the rash. When using sunscreen, be sure to use a light sunscreen, not too greasy, and loose, light clothing. Occlusive sunscreens and clothing can worsen the manifestations of versicolor versicolor.

Fungal acne

To be honest, dermatologists cringe a little when they hear the popular term “fungal acne” or “fungal acne” on social media. This is because “fungal pimples” are not actually pimples, but rather a form of folliculitis, or inflammation of the hair follicle. Folliculitis can be caused by many different organisms, such as bacteria, viruses, or yeast. On the other hand, folliculitis can also be sterile, that is, not be caused by any pathogen. In such cases, it can be caused by medications, friction, or thick, coarse hair.

When folliculitis is caused by the fungus Malassezia, it is called Pityrosporum Folliculitis (fungal acne). It appears as multiple small, itchy bumps and pimples, usually on the upper back and chest. It can also occur on the forehead/hairline, chin, neck, and upper arms. The main distinguishing features of fungal acne from true acne are that fungal acne is monomorphic (that is, all pimples and bumps are the same size and shape), and there are no blackheads and whiteheads. Sometimes a biopsy of the skin or pimple is needed to diagnose yeast.

Malassesia overgrowth treatment

Since all of these diseases are caused by the same pathogen (yeast), the treatments are similar and should be aimed at reducing the number of this fungus.

Dermatologists most commonly prescribe creams, shampoos, or antifungal tablets such as ketoconazole or fluconazole to treat fungal infections of the skin.

In addition, there are several over-the-counter products that also work great. The best yeast-fighting products contain ingredients such as zinc pyrithione or selenium sulfide. You can include these drugs in your skincare routine and alternate them with other products, or you can completely replace them with them. To maximize the effect of these products, soak them on the skin for 10 minutes before rinsing off.

Another remedy you may hear about is tea tree oil. Tea tree oil has been shown to be antimicrobial and may be helpful in treating yeast-related illnesses. Be careful when using tea tree oil: it can cause irritation or allergic contact dermatitis in some people. If you want to try a tea tree oil product, first test it for a few weeks on a patch of skin on the inside of your arm to see how it works. Avoid olive oil products as it is food for yeast and can aggravate skin conditions!

Here are some of my favorites:

Dove Dermacare Moisturizing Anti-Dandruff Shampoo with Coconut Scent

Bosley Anti-Dandruff Shampoo with Pyrithione Zinc

90 003

Petal Fresh Hair ResQ™ Conditioner

Herban Cowboy Sport Exfoliating Soap

Vanicream Z-Bar Anti-Dandruff Medical Soap

Selsun Blue Anti-Dandruff, Itch & Dry Skin Shampoo

Giovanni Tea Tree Triple Treat™ Shampoo

Balsa m with tea tree oil M3 Naturals

Attention! This blog is not intended for diagnosis, treatment or medical advice.